Mebendazole: Difference between revisions
ClaireLewis (talk | contribs) |
ClaireLewis (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antiparasitic]] (used to treat nematodes) | *Type: [[Antiparasitic]] (used to treat nematodes) | ||
*Dosage Forms: | *Dosage Forms: Tablet 100mg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: Emverm | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 45: | Line 45: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 23:08, 22 September 2019
Administration
- Type: Antiparasitic (used to treat nematodes)
- Dosage Forms: Tablet 100mg
- Routes of Administration: Oral
- Common Trade Names: Emverm
Adult Dosing
- 100mg PO BID x 3 days
Pediatric Dosing
≥2yo: 100mg PO BID x 3 days
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic impairment: may need dose reduction
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Agranulocytosis
- Hepatitis
- Seizure
- Angioedema
Common
- Abdominal pain, diarrhea
Pharmacology
- Half-life: 0.8-11.5h
- Metabolism: Hepatic
- Excretion: Fecal
Mechanism of Action
- Causes parasitic microtubules to degenerate, inhibiting glucose uptake and glycogen storage